We present nine cases of COVID-19 patients that developed pneumonia caused by SARSCov-2 who were seen in the Peruvian Central Air Force Hospital and showed different clinical features, risk factors, and outcomes. Findings of their thorax CT scans are described using a tomographic score that was applied on admission. Points assigned were based on the percentage of involvement on each pulmonary lobe and this allowed us to determine a clinical diagnosis of pneumonia according to its severity, even before having positive results in molecular and serological tests for some of these patients.

The case of the first deceased in Peru is presented. 78-year-old man, with a history of hypertension, who presented a characteristic clinical picture of the disease caused by the new coronavirus (COVID-19), which had fundamental epidemiological data, the positive confirmatory test together with some laboratory parameters and radiological image also characteristic; that followed a fatal evolution, despite receiving the recommended therapy at that time. This case highlighted the need to quickly identify those patients who could have an unfavorable evolution, in order to provide the earliest and most adequate treatment.

We present the case of a 44-year-old male patient, health personnel with high blood pressure, who had contact with patients with COVID-19 pneumonia. He had rapidly clinically-radiologically progressive lung involvement, received evidence-based treatment at admission, and an interleukin-6 receptor antagonist (tocilizumab) for compassionate use, obtaining a favorable clinical response.

We present nine cases of COVID-19 patients that developed pneumonia caused by SARSCov-2 who were seen in the Peruvian Central Air Force Hospital and showed different clinical features, risk factors, and outcomes. Findings of their thorax CT scans are described using a tomographic score that was applied on admission. Points assigned were based on the percentage of involvement on each pulmonary lobe and this allowed us to determine a clinical diagnosis of pneumonia according to its severity, even before having positive results in molecular and serological tests for some of these patients.

Objective: To describe the effects of the 5% lidocaine patch on the symptomatic relief of Peruvian patients with postherpetic neuralgia. Methods: Case series report of adult patients with post-herpetic neuralgia admitted to and treated at the Air Force Central Hospital in Lima. Symptomatic relief was defined as the difference between the specified pain score before and after patch treatment. The pain score was evaluated by the visual analogue scale and the Pain Assessment in Advanced Dementia scale, for patients with dementia. Results: Twenty-two patients with postherpetic neuralgia (mean age 74.4 ± 12.40 years) were recruited, 17 of whom began topical therapy with lidocaine following oral systemic treatment. The main reasons for the decision to change were a persistent pain and the adverse effects of the preceding therapy. A statistically significant decrease in pain symptoms was obser...